This site is intended for healthcare professionals
News

FDA approves Lybalvi for schizophrenia and bipolar I disorder.- Alkermes

Read time: 1 mins
Last updated:2nd Jun 2021
Published:2nd Jun 2021
Alkermes announced that the FDA has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.
Condition: Schizophrenia + Bipolar Disorder
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest